Shenzhen YHLO Biotech Bilan de santé
Santé financière contrôle des critères 6/6
Shenzhen YHLO Biotech has a total shareholder equity of CN¥2.6B and total debt of CN¥842.0M, which brings its debt-to-equity ratio to 32.4%. Its total assets and total liabilities are CN¥4.1B and CN¥1.5B respectively. Shenzhen YHLO Biotech's EBIT is CN¥243.5M making its interest coverage ratio 88.1. It has cash and short-term investments of CN¥578.4M.
Informations clés
32.4%
Ratio d'endettement
CN¥841.98m
Dette
| Ratio de couverture des intérêts | 88.1x |
| Argent liquide | CN¥578.39m |
| Fonds propres | CN¥2.60b |
| Total du passif | CN¥1.49b |
| Total des actifs | CN¥4.09b |
Mises à jour récentes de la santé financière
Recent updates
Estimating The Intrinsic Value Of Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575)
Oct 31
Shenzhen YHLO Biotech (SHSE:688575) Is Reinvesting At Lower Rates Of Return
Oct 12Shenzhen YHLO Biotech Co., Ltd.'s (SHSE:688575) Price In Tune With Earnings
Aug 30Does Shenzhen YHLO Biotech (SHSE:688575) Have A Healthy Balance Sheet?
Jul 18Shenzhen YHLO Biotech Co., Ltd. (SHSE:688575) Not Lagging Market On Growth Or Pricing
May 23Shenzhen YHLO Biotech's (SHSE:688575) Sluggish Earnings Might Be Just The Beginning Of Its Problems
May 01There Are Reasons To Feel Uneasy About Shenzhen YHLO Biotech's (SHSE:688575) Returns On Capital
Mar 19Analyse de la situation financière
Passif à court terme: 688575's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥887.7M).
Passif à long terme: 688575's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥600.0M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 688575's net debt to equity ratio (10.1%) is considered satisfactory.
Réduire la dette: 688575's debt to equity ratio has reduced from 49.4% to 32.4% over the past 5 years.
Couverture de la dette: 688575's debt is well covered by operating cash flow (87.2%).
Couverture des intérêts: 688575's interest payments on its debt are well covered by EBIT (88.1x coverage).